Psychiatry

Patient Care Services

Faculty

Grand Rounds

ECT

Substance Abuse

Geriatric Outreach

Research

Research Faculty

Research Staff

Studies Recruiting

Residency Program

for Residents/Applicants

for Medical Students

for Patients & Families

Psychiatry Education Fund

Contact

WFUBMC Home

>

Psychiatry

>

Research

>

Research Faculty

>

Peter Rosenquist

Peter Rosenquist, MD   Associate Professor   Biographical Sketch Dr. Rosenquist is currently Associate Professor in the Department of Psychiatry and Behavioral Medicine at Wake Forest University School of Medicine and is the Medical Director of Carolina Behavioral Health Alliance. He completed his medical degree from the University of Nebraska College of Medicine and post-graduate psychiatric training at Chicago Medical School. He is board certified in general psychiatry. His research interests include depressive disorders, neurodevelopmental disorders, brain stimulation therapies including electroconvulsive therapy and transcranial magnetic stimulation. He is on the Editorial Board of the Journal of ECT, and is on the Board of the Academic Behavioral Health Consortium. Department Name:   Psychiatry and Behavioral Medicine Office Phone:   (336) 716-4551 Fax:   (336) 716-6830 Email:   rosenqui@wfubmc.edu       Education     Postgraduate:   University of Nebraska College of Medicine, M.D.       Residency Training:   Chicago Medical School       Board Certification:   American Board of Psychiatry and Neurology, Inc. (General Psychiatry)       Research Interests     Electroconvulsive therapy Transcranial magnetic stimulation therapy Neuropsychiatric treatment of developmental disorders       Relevant Publications     McCall WV, Arias L, Onafuye R, Rosenquist PB. What the Electroconvulsive Therapy Practitioner Needs to Know About Obstructive Sleep Apnea. J ECT. 2008 Jun 23. Kimball JN, Rosenquist PB, Dunn A, McCall V. Prediction of antidepressant response in both 2.25xthreshold RUL and fixed high dose RUL ECT. J Affect Disord. 2008 Jun 6. Elliott HW, Arnold EM, Brenes GA, Silvia L, Rosenquist PB. Attention deficit hyperactivity disorder accommodations for psychiatry residents. Acad Psychiatry. 2007 Jul-Aug;31(4):290-6. Rosenquist PB, Dunn A, Rapp S, Gaba A, McCall WV. What predicts patients' expressed likelihood of choosing electroconvulsive therapy as a future treatment option? J ECT. 2006 Mar;22(1):33-7. Rosenquist PB, Brenes GB, Arnold EM, Kimball J, McCall V. Health-related quality of life and the practice of electroconvulsive therapy. J ECT. 2006 Mar;22(1):18-24. Review. Dew RE, Rosenquist PB, McCall WV. Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome. Int J Adolesc Med Health. 2005 Apr-Jun;17(2):187-8. Dew RE, Kimball JN, Rosenquist PB, McCall WV. Seizure length and clinical outcome in electroconvulsive therapy using methohexital or thiopental. J ECT. 2005 Mar;21(1):16-8. McCall WV, Dunn A, Rosenquist PB. Quality of life and function after electroconvulsive therapy. British Journal of Psychiatry 185, 405-409, 2004. Iodice AJ, Dunn AG, Rosenquist P, Hughes DL, McCall WV. The stability over time of patient attitudes towards ECT. Psychiatry Research 117: 89-91, 2003. McCall WV, Dunn AG, Rosenquist P, Hughes D. Proxy validation of patient self-reports of ADL and IADL function before and after electroconvulsive therapy. The Journal of ECT 18:74-79, 2002. Rosenquist PB, McCall WV, Colenda CC. A comparison of visual and computer-generated measures of seizure quality. Convulsive Therapy, Journal of ECT 1998; 14(2):76-82. McCall WV, Sparks W, Jane J, Rosenquist PB, Colenda CC, Reboussin DM. Variation of ictal encephalographic regularity with low-, moderate-, and high-dose stimuli during right unilateral electroconvulsive therapy. Biol Psychiatry 1998;43:608-611. Rosenquist PB, Bodfish JW, Thompson R. Tourette's Syndrome associated with mental retardation: A single subject treatment study with haloperidol. Am J Mental Retardation 1997;101(5), 497-504. Rosenquist PB, Bodfish JW. Neuropsychiatric movement disorders in those with mental retardation or developmental disability. Psychiatric Annals 1997;27(3):213-218. Rosenquist PB. Tourette's syndrome and obsessive compulsive disorder: Treatable causes of complex repetitive movements in mental retardation/developmental disability. In Poindexter A, ed, Evaluation and Management of Anxiety Disorders In Persons With Mental Retardation, National Association for the Dually Diagnosed (Mental Health and Mental Retardation), 1995, 31-39. Rosenquist PB, McCall WV, Farah A, Reboussin DM. The effects of caffeine pretreatment on measures of seizure impact. Convulsive Therapy 1994;10(2):181-185. McCall WV, Reid S, Rosenquist P, Foreman A, Kiewsow-Webb, N. A reappraisal of the role of caffeine in ECT. Am J Psychiatry 1993;150:1543-1545. Research Funding Sponsored by Neuronetics. A randomized, parallel-group, sham-controlled, multi-center study to evaluate the efficacy and safety of the Neuronetics Model 2100 CRS repetitive transcranial magenetic stimulation (rTMS) system in patients with major depression. Principal Investigator, 20% effort. Direct Costs: $242,515. 2/1/04-2/1/06. NIMH R01 MH61564 “Optimization of Electroconvulsive Therapy”. Vaughn McCall Principal Investigator, 18% effort. Direct costs: $787,500. 2/5/01-2/4/06. This project also receives logistical support from NIH GCRC grant M01-RR07122